ArticleNeuropsychiatric disease and treatment2026
Exploring the Therapeutic Potential and Mechanism of Qiangzhi Fang in a Rat Model of Tic Disorder with ADHD: Behavioral and Molecular Insights.
Article in Neuropsychiatric disease and treatment, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Tic disorder (TD) frequently co-occurs with attention-deficit/hyperactivity disorder (ADHD) and is associated with greater symptom severity and limited treatment options. Qiangzhi Fang is a Traditional Chinese Medicine (TCM) herbal formula that has been clinically used for neurobehavioral disorders, but its experimental evidence and mechanisms remain insufficiently characterized. Objective: To evaluate the behavioral effects of Qiangzhi Fang in a drug-induced rat model of TD comorbid with ADHD and to explore potential striatal molecular mechanisms. Methods: A drug-induced TD+ADHD rat model was established in male Sprague-Dawley rats. Animals were assigned to control, model, and Qiangzhi Fang treatment groups (low, medium, and high doses). Behavioral assessments included stereotypic behavior scoring (tic-like behaviors), locomotor activity (hyperactivity), anxiety-related behavior, and spatial learning and memory. Striatal expression of tyrosine hydroxylase (TH) and phosphorylated Ca Results: Qiangzhi Fang treatment ameliorated TD- and ADHD-like behavioral abnormalities, including reduced stereotypic movements, decreased hyperactivity, and improved spatial learning and memory performance, with the most pronounced effects observed at higher doses. At the molecular level, treatment was associated with downregulation of striatal TH and p-CaMKII expression. These markers reflect alterations in dopamine synthesis and synaptic signaling; however, dopamine levels, receptor subtypes, and neural circuitry were not directly assessed. Conclusion: Qiangzhi Fang improved behavioral phenotypes in a preclinical rat model of TD comorbid ADHD and was associated with changes in striatal TH and p-CaMKII expression. These findings suggest a possible neuromodulatory role of Qiangzhi Fang, although the mechanistic evidence remains preliminary. This study may provide an experimental basis for further investigation of herbal formulations in TD and ADHD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.